首页|参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并心功能不全的效果及对心血管不良事件的影响

参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并心功能不全的效果及对心血管不良事件的影响

Effect of Shensong Yangxin capsules combined with sacubitril valsartan in the treatment of paroxysmal atrial fibrillation complicated with cardiac insufficiency and its influences on cardiovascular adverse events

扫码查看
目的 分析参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并心功能不全的效果及对心血管不良事件的影响.方法 选取我院 2020 年 2月至2023年 2月收治的76 例阵发性心房颤动合并心功能不全患者作为研究对象,以随机法将其分为常规组(38 例,沙库巴曲缬沙坦治疗)和观察组(38 例,参松养心胶囊联合沙库巴曲缬沙坦治疗).比较两组的临床疗效、心功能指标、心率变异性指标、心血管不良事件及不良反应发生情况.结果 观察组的治疗总有效率高于常规组(P<0.05).治疗后,观察组的左心室射血分数(LVEF)、窦性心率R-R间期总体标准差(SDNN)与相邻正常R-R间期差值均方根(rMSSD)显著高于常规组,左心室收缩末期内径(LVESD)、左心室收缩末期容积(LVESV)与左心室舒张末期容积(LVEDV)显著低于常规组(P<0.05).观察组治疗期间的心血管不良事件总发生率显著低于常规组(P<0.05).两组治疗期间的不良反应总发生率比较,差异无统计学意义(P>0.05).结论 参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并心功能不全患者可获得安全高效的理想效果.
Objective To analyze the effect of Shensong Yangxin capsule combined with sacubitril valsartan in the treatment of paroxysmal atrial fibrillation complicated with cardiac insufficiency and its influences on cardiovascular adverse events.Methods A total of 76 patients with paroxysmal atrial fibrillation complicated with cardiac insufficiency admitted in our hospital from February 2020 to February 2023 were selected as the research objects,and the patients were randomly divided into routine group(38 cases,sacubitril valsartan treatment)and observation group(38 cases,Shensong Yangxin capsule combined with sacubitril valsartan treatment).The clinical efficacy,cardiac function indexes,heart rate variability indexes,cardiovascular adverse events and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the routine group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF),standard deviation of the R-R interval(SDNN)and root mean square of successive R-R interval differences(rMSSD)in the observation group were significantly higher than those in the routine group,while the left ventricular end-systolic diameter(LVESD),left ventricular end-systolic volume(LVESV)and left ventricular end-diastolic volume(LVEDV)were significantly lower than those in the routine group(P<0.05).The total incidence of cardiovascular adverse events during treatment in the observation group was significantly lower than that in the routine group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Shensong Yangxin capsule combined with sacubitril valsartan in the treatment of patients with paroxysmal atrial fibrillation complicated with cardiac insufficiency can obtain safe and efficient ideal effect.

paroxysmal atrial fibrillationcardiac insufficiencyShensong Yangxin capsulesacubitril valsartan

张正伟、崔志娟、申鹏超

展开 >

伊川县中医院内一科病区,河南 洛阳,471300

阵发性心房颤动 心功能不全 参松养心胶囊 沙库巴曲缬沙坦

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(18)